|
The document is a final report on a health study investigating the relationship between self-reported medical conditions, including cancers, and employment at a perfluorooctanesulfonyl fluoride (POSF) production facility, specifically focusing on PFOS exposure among workers at the 3M facility in Decatur, Alabama.
|
2006 |
AR226-3732
|
a4xZqZgNnMoyJ0Zq6eELxXmQX |
26 |
|
DuPont provided preliminary partial non-occupational blood data on perfluorooctanoic acid (PFOA) collected from communities in West Virginia and Ohio to the EPA, acknowledging that they do not have access to the complete dataset from Brookmar, which is conducting the study independently.
|
2006 |
AR226-3736
|
vVNXr44yORbjpaD7RrxwXmErm |
3 |
|
The document outlines preliminary protocols for a health study on the effects of exposure to C8 (PFOA) around the Washington Works plant, emphasizing the confidentiality of initial data received from Brookmar and cautioning against drawing conclusions from it.
|
2006 |
AR226-3737
|
k9Eqvdk1omMZZ2Q2mp1ZJ6vKb |
1 |
|
The document presents statistical data on C8 (PFOA) blood levels among a community cohort of 23,942 participants aged 20 and older, detailing mean and median levels, demographic information, and distribution across different water districts in relation to drinking water sources.
|
2006 |
AR226-3738
|
2jzbD0kbJa8pokBR3rEz562LR |
6 |
|
The document is a submission from DuPont's legal counsel, Andrea V. Malinowski, to the EPA regarding a baseline study/report on PFOA and PFOS conducted in Pascagoula, Mississippi, which has also been provided to state environmental agencies.
|
2006 |
AR226-3741
|
2qEV5YR2jdNVoDzYLkvXL5gmg |
1 |
|
The document presents preliminary analyses of pregnancy outcomes among women, including miscarriage and birth defect rates, in relation to potential exposure to perfluorinated compounds, specifically focusing on data from a study involving 18,276 women and 48,007 pregnancies.
|
2006 |
AR226-3740
|
jmeem206B4B6m7aEnLx6ZrzJ2 |
3 |
|
This document is a report from Daikin America, Inc. submitted to the EPA detailing the material balance of Perfluorooctanoic Acid (PFOA) for their Decatur Plant in 2005, including a comparison to data from 2000.
|
2006 |
AR226-3730
|
MG6Xga5x53XDOn054o5X8YgQ9 |
2 |
|
This document is a submission by 3M to the EPA regarding additional information on a mortality study and subsequent health incidence study related to perfluorooctanesulfonyl fluoride (POSF) manufacturing workers, highlighting a final report on self-reported medical conditions that examined various health endpoints, including cancer.
|
2006 |
AR226-3731
|
Gmnw9OZN30dVzvyzDzXMrjadv |
2 |
|
DuPont submitted updated occupational blood monitoring information for Perfluorooctanoic Acid (PFOA) to the EPA, reporting serum sample results from Axys Analytical Services that corroborate previous findings, with PFOA levels ranging from 7.71 ng/mL to 2630 ng/mL and consistent results within 20% of those reported by Exygen Laboratories.
|
2006 |
AR226-3733
|
dnpZV5rkK75wBxqxKzk4DNrGQ |
3 |
|
The Pascagoula Baseline Study/Report for First Chemical Corporation details the sampling and analysis of water and solids in Pascagoula, Mississippi, focusing on the occurrence of PFOA and PFOS, with findings related to their presence in surface water, groundwater, and sludge.
|
2006 |
AR226-3742
|
DGwvG99g2Dzgb0rrN8ayvx85 |
40 |
|
The document contains analytical results from various DuPont facilities regarding the detection and quantification of perfluorinated compounds, including PFOA and PFOS, with specific recovery rates and concentration measurements.
|
2006 |
AR226-3734
|
mmokap5Q7yLaYpjQj7LXvGp4k |
4 |
|
The document is a final report on a health study investigating the relationship between self-reported medical conditions, including cancers, and employment at a perfluorooctanesulfonyl fluoride (POSF) production facility, specifically focusing on PFOS exposure among workers at the 3M facility in Decatur, Alabama.
|
2006 |
AR226-3732
|
ba2em1xkZ6mY178bDdvR469Yg |
26 |
|
This is an analytical report from Axys Analytical Services detailing the results of perfluorinated compounds analysis in serum samples, with sample receipt dated February 20, 2006, and analysis conducted on March 30, 2006.
|
2006 |
AR226-3735
|
ZBDOYQDQNJBkxJxxxyZY6Z0BJ |
3 |
|
DuPont submitted preliminary partial non-occupational blood data related to perfluorooctanoic acid (PFOA) collected from communities in West Virginia and Ohio to the EPA, highlighting that the data is incomplete and derived from a study not directed by DuPont.
|
2006 |
AR226-3736
|
71J9Q2LdrDw1LLj3yV2DZVo9j |
3 |
|
This document is a submission by 3M to the EPA regarding additional information on a mortality study and subsequent health incidence study of workers at a perfluorooctanesulfonyl fluoride (POSF)-based fluorochemical manufacturing facility, highlighting findings related to bladder cancer and other health conditions reported by workers.
|
2006 |
AR226-3731
|
G6yjvQOvEQB0V3woN5O66x6V |
2 |
|
This document is a report from Daikin America, Inc. submitted to the EPA detailing the material balance of Perfluorooctanoic Acid (PFOA) for their Decatur Plant in 2005, including a comparison to the year 2000.
|
2006 |
AR226-3730
|
LKGNJe21g4vRDKKwLDGkeZGn7 |
2 |
|
DuPont submitted updated occupational blood monitoring information for Perfluorooctanoic Acid (PFOA) to the EPA, reporting serum sample results from Axys Analytical Services that corroborate previously reported levels, with PFOA concentrations ranging from 7.71 ng/mL to 2630 ng/mL and consistent results compared to Exygen Laboratories.
|
2006 |
AR226-3733
|
3Q2dLmy8VGLLaEavLZOoojm2a |
3 |
|
The document reports on a health study investigating self-reported medical conditions, including cancers, among employees at a 3M facility in Decatur, Alabama, potentially linked to exposure to perfluorooctanesulfonyl fluoride (POSF) and perfluorooctanesulfonate (PFOS).
|
2006 |
AR226-3732
|
pmv17Z5z2OGLanbK1w2xKXN7w |
26 |
|
DuPont submitted a document to the EPA containing analytical results for perfluorinated organics, specifically from a report by Axys Analytical Services requested by the Little Hocking Water Association, but DuPont does not verify the validity of the results.
|
2006 |
AR226-3581
|
L6R5g8vBoyXV2Ng1g93odkbw |
8 |
|
This document is a follow-up letter from DuPont to the EPA regarding an oral repeated dose toxicity study in rats and mice involving linear and branched forms of perfluorooctanoic acid (APFO).
|
2006 |
AR226-3582
|
0gobp9v493YxK520q7D8DmDpx |
2 |
|
This document is a report from Daikin America, Inc. submitted to the EPA detailing the material balance for Perfluorooctanoic Acid (PFOA) at their Decatur Plant for the year 2005, including a comparison to data from 2000.
|
2006 |
AR226-3730
|
QgbpqOx5Qw47NbrYLa7xLbbg4 |
2 |
|
The document discusses a submission by 3M to the EPA regarding additional information on a mortality study and subsequent health incidence study of workers at a perfluorooctanesulfonyl fluoride (POSF)-based fluorochemical manufacturing facility, highlighting findings related to bladder cancer and other health conditions reported by workers.
|
2006 |
AR226-3731
|
KRn2jeq9ZZoLOdMKKoxLJ2mBN |
2 |
|
DuPont submitted updated occupational blood monitoring information for perfluorooctanoic acid (PFOA) to the EPA, reporting that serum samples analyzed by Axys Analytical Services showed PFOA levels ranging from 7.71 ng/mL to 2630 ng/mL, which were consistent with previous findings from Exygen Laboratories.
|
2006 |
AR226-3733
|
ZBbxqGnkQZK0V2djyv38q037 |
3 |
|
The document contains analytical results for various perfluorinated compounds, including PFOA and PFOS, from samples collected at DuPont facilities, detailing recovery rates and concentrations detected in the samples.
|
2006 |
AR226-3734
|
Rad7znvGO2oBDp5aVzDMzQnwk |
4 |
|
The document is a final report on a health study investigating self-reported medical conditions, including cancers, among employees at a 3M facility in Decatur, Alabama, potentially linked to exposure to perfluorooctanesulfonyl fluoride (POSF) and perfluorooctanesulfonate (PFOS).
|
2006 |
AR226-3732
|
bbkoy23wXDBNvNe2N6yGx4xZ |
26 |
|
This document includes analytical reports from Axys Analytical Services detailing the analysis of serum samples for various perfluorinated compounds, specifically related to job number WG18498.
|
2006 |
AR226-3735
|
nkrLJR0eNNKNkoJpZeojy5YOm |
3 |
|
The document outlines preliminary protocols for a health study on the effects of exposure to C8 (PFOA) around the Washington Works plant, emphasizing the confidentiality of initial data received and cautioning against premature public dissemination of findings.
|
2006 |
AR226-3737
|
DGbVL1egRmgjNoLdJ8GeaXvbM |
1 |
|
DuPont provided preliminary partial non-occupational blood data on perfluorooctanoic acid (PFOA) collected from communities in West Virginia and Ohio to the EPA, noting that they do not have access to the complete dataset from Brookmar, which is conducting the study independently.
|
2006 |
AR226-3736
|
mqyJnYe0GokK0w3G0Gawz1gog |
3 |
|
The document presents statistical data on C8 (PFOA) blood levels among a community cohort in 2005, detailing demographics, body mass index, and distribution of C8 concentrations across different water districts.
|
2006 |
AR226-3738
|
jZxL0gOdZO2DdQ4OJg6pkEZk |
6 |
|
The document presents preliminary analyses of pregnancy outcomes among women, including miscarriage, stillbirth, and birth defects, in relation to exposure to perfluorinated compounds, specifically focusing on data from 18,276 women and estimating total pregnancy outcomes based on initial findings.
|
2006 |
AR226-3740
|
zbMmzDxZNQ6oED1z0wrEgwB6B |
3 |
|
The document is a submission from DuPont's legal counsel to the EPA, providing a report on a baseline study of PFOA and PFOS sampling conducted in Pascagoula, Mississippi, for informational purposes.
|
2006 |
AR226-3741
|
6wge9zj973gykeEn1Qo1K9qqm |
1 |
|
This document provides updated occupational serum sampling results for perfluorooctanoic acid (PFOA) from employees at the First Chemical Corporation in Pascagoula, Mississippi, indicating that PFOA levels in 2006 are consistent with those found in a 2003 sampling and comparable to levels reported in the general population.
|
2006 |
AR226-3745
|
o93xzGeerQoQq7kEmEo9ZRLY7 |
2 |
|
A retrospective exposure analysis estimated potential residential intake of perfluorooctanoic acid (PFOA) from a manufacturing facility in Ohio and West Virginia, identifying air emissions and soil transfer as the primary sources of PFOA contamination in groundwater over a 53-year period.
|
2006 |
AR226-3744
|
G5g0zDbgz0y3VDYkp28D7pgQm |
11 |
|
The Pascagoula Baseline Study/Report for First Chemical Corporation details the sampling and analysis of water and solids in the Pascagoula region, specifically focusing on the occurrence of PFOA and PFOS, with findings discussed in relation to surface water, groundwater, and POTW sludge.
|
2006 |
AR226-3742
|
K6MMwBve0xXY6rGXgeVLven72 |
40 |
|
DuPont submitted a document to the EPA regarding an analytical report on Perfluorinated Organics, specifically noting that the results were obtained from AXYS laboratory at the request of the Little Hocking Water Association, but DuPont does not verify the validity of the findings.
|
2006 |
AR226-3581
|
0gNRDkkR6zbd0GO3KRe9qxanM |
8 |
|
This document is a follow-up letter from DuPont to the EPA regarding an oral repeated dose toxicity study in rats and mice involving linear and branched forms of perfluorooctanoic acid (APFO).
|
2006 |
AR226-3582
|
DMq40Gg9dvrRoKVMYJ6VqRVq5 |
2 |
|
This document is a letter from DuPont to the EPA reporting the results of private well water sampling for perfluorooctanoic acid (PFOA) near the Fayetteville Works facility, indicating no detectable PFOA in one well and a low concentration of 0.011 parts per billion in another.
|
2006 |
AR226-3584
|
o9n7RY2r4r8VYy3Jw7X635woE |
1 |
|
This document is a letter from DuPont's Corporate Remediation Group submitting final reports on private well water sampling for Perfluorooctanoic Acid (PFOA) in Fayetteville, North Carolina, as referenced in a previous communication dated January 18, 2006.
|
2006 |
AR226-3586
|
ybGRJrXRNwdvLaYrbwkbz08z3 |
1 |
|
The document is a correspondence from Asahi Glass Company, Ltd. to the EPA discussing their efforts to reduce exposure to PFOA and their willingness to engage in industry-wide voluntary exposure reduction programs.
|
2006 |
AR226-3585
|
6bxeexnGo0qOBjbZKxgLd1Bx6 |
5 |
|
This document is a correspondence from Taft, Stettinius & Hollister LLP to the EPA, providing additional exposure and monitoring data on perfluorochemicals (PFCs) for inclusion in the administrative record AR-226, specifically referencing a final report on PFC contamination in Minnesota.
|
2006 |
AR226-3589
|
8V1GXO9V9JkDV1KX684KO9Q7K |
2 |
|
This analytical report from Severn Trent Laboratories details the results of PFOA analysis for E. I. DuPont's Fayetteville, NC project, confirming compliance with laboratory quality standards and NELAC requirements.
|
2005 |
AR226-3588
|
9oZE6LQK50m8z9ondXqEKaeR |
79 |
|
The document provides an update on Environment Canada's ecological risk assessment activities for perfluoroalkyl substances, specifically focusing on PFOS, and discusses the categorization and potential environmental impacts of these substances in Canada.
|
2005 |
AR226-3592
|
peeNxnx6R455EyX65M89xaNj |
1 |
|
This document is a revision of a study conducted by E.I. du Pont de Nemours and Company on the effects of linear and branched APFO (perfluorooctanoic acid) through a 14-day oral gavage in male rats and mice, ensuring compliance with Good Laboratory Practice standards.
|
2005 |
AR226-3583
|
wDyroQ0RqK9abjGRyJK6DZ856 |
414 |
|
The document discusses the invitation to submit information regarding five chemicals, including Perfluorooctane sulfonate (PFOS), for consideration by the Stockholm Convention's Persistent Organic Pollutants Review Committee, which has determined that the screening criteria for these substances have been met for further evaluation.
|
2005 |
AR226-3610
|
rpqOj7MzkbZRR4jjOR3nXz17E |
6 |
|
The document reports on the first meeting of the Persistent Organic Pollutants Review Committee established under the Stockholm Convention, focusing on organizational matters and the election of committee officials, without specific mention of PFOA or PFOS.
|
2005 |
AR226-3609
|
6Yj8Yvy8y6gjxQxmrkRqBxgR |
35 |
|
The document discusses a proposal submitted by the Government of Sweden for the inclusion of perfluorooctane sulfonate in Annex A of the Stockholm Convention on Persistent Organic Pollutants, with the Committee considering whether the proposal meets the necessary requirements for further action.
|
2005 |
AR226-3612
|
reKNgvBdr51DLazJvrzgEeBVa |
4 |
|
This document is an addendum to the PFOS dossier submitted by Sweden to the Persistent Organic Pollutants Review Committee, providing an update on scientific literature from June 2004 to October 2005 that reinforces the conclusion that perfluorooctane sulfonate (PFOS) meets the criteria for persistent organic pollutants due to its bioaccumulation and biomagnification in food webs.
|
2005 |
AR226-3613
|
91OLgkgq92yJeQQZLKQae7Bmq |
15 |
|
This document is a list of participants from various countries attending the first meeting of the Persistent Organic Pollutants Review Committee held by the United Nations Environment Programme in Geneva from November 7-11, 2005.
|
2005 |
AR226-3615
|
6w7gRo9Rmo5JNza4rgeqxKgR4 |
12 |
|
The document is a notice from the EPA regarding the proposal to add certain substances, including perfluorinated compounds, to the 1998 Aarhus Persistent Organic Pollutants (POPs) Protocol under the UNECE, aimed at controlling and reducing harmful emissions.
|
2005 |
AR226-3616
|
7RyKEQroOyJ46VkBZzNm3zYLR |
2 |
|
This is a progress report by the Co-Chairmen of the Task Force on Persistent Organic Pollutants (POPs) detailing the outcomes of meetings held in Vienna and Rome, including technical reviews of pentabromodiphenyl ether (PeBDE) and perfluorooctane sulfonate (PFOS) as part of the review of the Protocol on POPs.
|
2005 |
AR226-3620
|
ppkvEw4Lx2YLXXNKzGvLne5YB |
20 |
|
This is a draft workplan for the Working Group on Strategies and Review prepared by the United Nations Economic Commission for Europe, outlining objectives and activities for assessing and reviewing protocols related to air pollution for the year 2006.
|
2005 |
AR226-3623
|
VNODpQ5gr5pyM9E9n3zpLdZq |
6 |
|
The document outlines the agenda and topics for the third meeting of the UNECE Task Force on Persistent Organic Pollutants, focusing on the technical review of substances including PFOS and the assessment of their environmental impacts and alternatives.
|
2005 |
AR226-3622
|
7O7o8aVDyYz01194mDovy7akg |
55 |
|
This interim report details the analysis of perfluorooctanoic acid (PFOA), perfluorobutanesulfonate (PFBS), perfluorohexanesulfonate (PFHS), and perfluorooctanesulfonate (PFOS) in various environmental samples as part of the 3M Cottage Grove Monitoring Program, conducted by Exygen
|
2005 |
AR226-3636
|
6R5X1y0OJbrQ5120DbQqqa2am |
63 |
|
This interim report details the analysis of perfluorooctanoic acid (PFOA), perfluorobutanesulfonate (PFBS), perfluorohexanesulfonate (PFHS), and perfluorooctanesulfonate (PFOS) in various environmental samples as part of the 3M Cottage Grove Monitoring Program, conducted by Exygen
|
2005 |
AR226-3642
|
dnD95nN5pYOpY3RJqjp2VQv1q |
63 |
|
This interim report details the analysis of perfluorooctanoic acid (PFOA), perfluorobutanesulfonate (PFBS), perfluorohexanesulfonate (PFHS), and perfluorooctanesulfonate (PFOS) in various environmental samples as part of the 3M Cottage Grove Monitoring Program, conducted by Exygen
|
2005 |
AR226-3648
|
ZJ2v3BnNN1O5NKn16z5L1wpOO |
63 |
|
3M submitted a communication to the EPA containing updated perfluorobutane sulfonate (PFBS) study reports, including new findings on avian reproductive toxicity and histopathology related to 90-day oral toxicity, along with an index and sanitized copies of previous reports.
|
2005 |
AR226-3748
|
B81KpxR0Ldw160akaygNBJg4E |
2 |
|
3M submitted a final report to the EPA regarding a study on sulfonate-based and carboxylic-based fluorochemicals, including preliminary data from 36 lots of human serum screened for endogenous fluorochemicals.
|
2005 |
AR226-3575
|
gQjJgDXZDajEdzOZDxkQaDmV |
1 |
|
3M submitted a final report to the EPA regarding a study on sulfonate-based and carboxylic-based fluorochemicals, including PFOA and PFOS, based on preliminary data from 36 lots of human serum screened for these substances.
|
2005 |
AR226-3577
|
3QRE3DNrZ8Ng5QYeVGMB5dOb0 |
1 |
|
3M submitted a final report to the EPA regarding a study on sulfonate-based and carboxylic-based fluorochemicals, including PFOA and PFOS, based on preliminary data from 36 lots of human serum screened for endogenous fluorochemicals.
|
2005 |
AR226-3579
|
gak7084y8RLJXmeBOMOZNNE1V |
1 |
|
3M submitted a TSCA Section 8(e) Supplemental Notice to the EPA, providing the final report on a study that screened 36 lots of human serum for the presence of sulfonate-based and carboxylic-based fluorochemicals, including PFOA and PFOS.
|
2005 |
AR226-3575
|
QJ9YaJr8n8p7onNQVpbEkXK2v |
1 |
|
3M submitted a final report to the EPA regarding a study on sulfonate-based and carboxylic-based fluorochemicals, including preliminary data from 36 lots of human serum screened for endogenous fluorochemicals.
|
2005 |
AR226-3577
|
5b8yKg2x8GMrNbXrk7OddZxN |
1 |
|
3M submitted a final report to the EPA regarding a study on sulfonate-based and carboxylic-based fluorochemicals, including preliminary data from 36 lots of human serum screened for endogenous fluorochemicals.
|
2005 |
AR226-3579
|
YDXOr02oajVM7EQ20kYkgdDKV |
1 |
|
This document is a letter from DuPont to the EPA providing supplemental information regarding an ongoing study on Ammonium Perfluorooctanoate (PFOA) that evaluates health status and serum biomarker exposure among employees at their Washington Works plant, indicating no clear associations between serum PFOA levels and proximity to the plant site.
|
2005 |
AR226-3542
|
DdY4M3znj33KrV0BYoj4Xz1M5 |
2 |
|
General Electric (GE) submitted corroborative data on Ammonium Perfluorooctanoate (APFO) and Perfluorooctanoic Acid (PFOA), indicating that the information does not significantly alter the current understanding of the risks posed by PFOA, while providing data on detectable levels of PFOA in polytetrafluoroethylene (PTFE) products
|
2005 |
AR226-3543
|
3Jy6eNXV3yY2dQrBjZaeQBXeE |
3 |
|
3M submitted a TSCA Section 8(e) Supplemental Notice to the EPA, providing screening data from an analytical report on human serum samples that detected perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA), indicating that the findings are preliminary and not necessarily representative of the general population.
|
2005 |
AR226-3547
|
4vm04zQdBmjZRaDnxROOk9a4R |
20 |
|
3M submitted a TSCA Section 8(e) Supplemental Notice to the EPA, providing an analytical report on the screening of human serum for fluorochemicals, including PFOS and PFOA, indicating that the detected levels do not represent "substantial risk" information.
|
2005 |
AR226-3548
|
mpzaapKO165vp1nK4vR4YVj14 |
20 |
|
3M submitted a TSCA Section 8(e) Supplemental Notice to the EPA, providing an analytical report on the screening of 36 lots of human serum for fluorochemicals, including PFOS and PFOA, indicating that the data is preliminary and not necessarily representative of general population levels.
|
2005 |
AR226-3549
|
5jK9NEG9Dno9daaxNqOv47gz |
20 |
|
DuPont submitted additional documents to the EPA on January 10, 2005, in response to a previous request regarding environmental monitoring, biodegradation, and analytical methods related to perfluorinated compounds, including PFOA and PFOS.
|
2005 |
AR226-3554
|
rpV0avXL0ay221DKxKa2GqQGE |
8 |
|
This document is a submission from 3M Specialty Materials to the EPA detailing the third round of groundwater and wastewater monitoring data for perfluorooctanoic acid (PFOA) at their manufacturing sites in Cottage Grove, MN, and Decatur, AL, as part of their commitments under the Letters of Intent dated March 2003.
|
2005 |
AR226-3557
|
QJBeno2MbDK4eVOjwLJz0Y8v8 |
13 |
|
The document is a correspondence from Andrea V. Malinowski of DuPont Legal regarding the environmental impact and regulatory considerations of Perfluorooctanoic Acid (PFOA) related to DuPont's operations in West Virginia.
|
2005 |
AR226-3560
|
EqLqxk7dN7OwGOOpabvyrwzmL |
1 |
|
The document is a correspondence from DuPont's Corporate Counsel to the EPA, enclosing letters between DuPont and the West Virginia Department of Environmental Protection regarding PFOA sampling results at the Dry Run Landfill, which were reported to be at or above 150 µg/L.
|
2005 |
AR226-3559
|
6JKKEE3gDRdJonYEjeXoJ82R |
10 |
|
3M submitted supplemental serum analysis results for children of two female fluorochemical plant workers, providing context from maternal serum levels, as part of their occupational medical surveillance program related to fluorochemicals.
|
2005 |
AR226-3564
|
6gzQQV46Zaag254XzBGV7GDR |
4 |
|
3M submitted a TSCA 8(e) supplemental report to the EPA indicating that PFOS was detected at approximately 0.1 ppb in surface water and municipal water at their production facility in Guin, Alabama, while PFOA and PFBS were non-detect.
|
2005 |
AR226-3565
|
B8vJEbGnV9467RQpz9Mx3xG9w |
1 |
|
3M submitted a TSCA 8(e) supplemental report to the EPA indicating that perfluorooctanesulfonate (PFOS) was detected at approximately 0.1 ppb in surface water and municipal water at their production facility in Guin, Alabama, while perfluorooctanoic acid (PFOA) and perfluorobutanesulfonate (
|
2005 |
AR226-3567
|
QG6z5MrLkE1g6OpeMONwVpZk |
1 |
|
This document from 3M provides supplemental serum analysis results for children of fluorochemical plant workers, detailing the sampling context and maternal serum levels for PFOA and other fluorochemicals.
|
2005 |
AR226-3569
|
YGpkvkK4MK9QgV16odBBegd30 |
4 |
|
3M submitted a supplemental report to the EPA indicating that PFOS was detected at approximately 0.1 ppb in surface and municipal water samples from a production facility in Guin, Alabama, while PFOA and PFBS were non-detect.
|
2005 |
AR226-3570
|
e5vMQzbgODjEVejXLeDGjXzRy |
1 |
|
This is a letterhead cover page from 3M, with no analytical content retained in the OCR.
|
2005 |
AR226-3572
|
XO9ydaKdbQdGgyO9g6e0gO58x |
2 |
|
3M submitted a final report to the EPA regarding a study on sulfonate-based and carboxylic-based fluorochemicals, including preliminary data from 36 lots of human serum screened for endogenous fluorochemicals.
|
2005 |
AR226-3575
|
DD7Dx1NG7jjbrxwyLRZ0Bxd3o |
1 |
|
3M submitted a final report to the EPA regarding a study on sulfonate-based and carboxylic-based fluorochemicals, including preliminary data from 36 lots of human serum screened for endogenous fluorochemicals.
|
2005 |
AR226-3577
|
44RKgr03L3MYxKRkY6RgR7d2Q |
1 |
|
3M submitted a final report to the EPA regarding a study on sulfonate-based and carboxylic-based fluorochemicals, including preliminary data from 36 lots of human serum screened for endogenous fluorochemicals.
|
2005 |
AR226-3579
|
oevMYjZBkxaOGYnK0o2gQ3e13 |
1 |
|
The document is a dossier prepared by the Swedish Chemicals Inspectorate and the Swedish EPA in August 2004, detailing the preliminary risk profile of perfluorooctane sulfonate (PFOS) in support of its nomination to the UN-ECE LRTAP Protocol and the Stockholm Convention, highlighting its chemical identity, environmental release, and potential risks.
|
2004 |
AR226-3621
|
7MDZv075G9nqybvZa6bEz1zDe |
45 |
|
The document presents blood serum PFOA levels among mechanics at various DuPont facilities, including Charleston, WV, and Deepwater, NJ, with findings indicating an average PFOA concentration of 18.01 ppb among sampled individuals.
|
2004 |
AR226-3652
|
rZX5Vo33rVymEV0X6aNYpnK7 |
10 |
|
The Michigan Department of Community Health issued an advisory regarding acute respiratory illnesses linked to aerosolized waterproofing products, specifically identifying Jobsite Heavy Duty Bootmate and Rocky Boot Weather and Stain Protector, both produced by Assured Packaging, which have resulted in numerous hospitalizations and at least three pet fatalities.
|
2004 |
AR226-3703
|
1gpQ67zvgvq1p17oLJMqNdy1E |
2 |
|
This analytical report from 3M Environmental Laboratory details the quantitative screening of thirty-six lots of commercially available human serum for endogenous fluorochemicals, including the exclusion of heptafluorobutyric acid (PFBA) due to instability, with plans for a separate study to analyze PFBA using a new method.
|
2004 |
AR226-3576
|
O3g9N1Y3zLgJB4mxvvN9o6Raj |
19 |
|
This analytical report from 3M Environmental Laboratory details the quantitative screening of thirty-six lots of commercially available human serum for endogenous fluorochemicals, including various perfluorinated compounds, using solid phase extraction and liquid chromatography/tandem mass spectrometry, although data for heptafluorobutyric acid (PFBA) was excluded due to instability issues.
|
2004 |
AR226-3578
|
RjRRywRzEre40D5ya3Y6ZKeOz |
19 |
|
This analytical report from 3M Environmental Laboratory details the screening of 36 lots of commercially available human serum for endogenous fluorochemicals, including PFOA and PFOS, using solid phase extraction and liquid chromatography/tandem mass spectrometry, while noting that data for PFBA was excluded due to instability issues.
|
2004 |
AR226-3580
|
DD485RK9pkJwgGME4qw5Ezkpo |
19 |
|
This analytical report from 3M Environmental Laboratory details the screening of thirty-six lots of commercially available human serum for sixteen different fluorochemicals, including the exclusion of heptafluorobutyric acid (PFBA) due to instability, with plans for a separate study to analyze PFBA using a new method.
|
2004 |
AR226-3576
|
NNkqYpgbjJ9mbvQw35d2aE3QQ |
19 |
|
This analytical report from 3M Environmental Laboratory details the screening of thirty-six commercial lots of human serum for endogenous fluorochemicals, including PFOA and PFOS, using solid phase extraction and liquid chromatography/tandem mass spectrometry, although data for PFBA was excluded due to instability issues.
|
2004 |
AR226-3578
|
by1Y8qYroRZNnNo5KrxyMVJyk |
19 |
|
This analytical report from 3M Environmental Laboratory details the quantitative screening of thirty-six commercial lots of human serum for sixteen endogenous fluorochemicals, including a note that data for heptafluorobutyric acid (PFBA) will not be included due to instability, with plans for a separate study to analyze PFBA using a new method.
|
2004 |
AR226-3580
|
3QEgaG7q6rv2Zv5R69wr4qVen |
19 |
|
The document is a letter from DuPont's attorney, Anthony F. Cavanaugh, to the EPA's Mary Dominiak, clarifying clerical errors in the submission of six boxes of documents related to C-8 (PFOA) air and water monitoring data.
|
2004 |
AR226-3550
|
pp75ZxRmpBrz8EGLEBkEygGpj |
43 |
|
This is a cover letter addressed to Ms. Mary Dominiak at the EPA's Document Control Office, dated November 19, 2004, indicating that the enclosed materials contain TSCA Confidential Business Information.
|
2004 |
AR226-3551
|
99v0ed8GXj3qyg7D15ygkz1J5 |
3 |
|
This is a letter from Patton Boggs dated December 10, 2004, addressed to Peter D. Robertson, regarding the submission of documents related to occupational blood monitoring as requested by the EPA.
|
2004 |
AR226-3553
|
b5xnyx2Vj411ankp4yLvZKQvD |
10 |
|
DuPont submitted a letter to the EPA detailing their voluntary response to a request for information regarding PFOA, including a modified timeline for submitting toxicology, pharmacokinetics, and monitoring reports.
|
2004 |
AR226-3552
|
3Q9MN2xw6Qzzo2pOX54d9pZg0 |
21 |
|
DuPont submitted additional epidemiology and industrial hygiene air monitoring data to the EPA in response to a request dated November 4, 2004, indicating their ongoing cooperation and belief that the information does not trigger reporting obligations under TSCA section 8.
|
2004 |
AR226-3555
|
YGw7bZKVrV6ZZ55Od20VJOMvy |
15 |
|
This is a letterhead cover page from Patton Boggs, with no analytical content retained in the OCR.
|
2004 |
AR226-3556
|
N7279oyO2w34BkDprb8n6Ynw |
4 |
|
This analytical report from 3M Environmental Laboratory details the quantitative screening of thirty-six lots of commercially available human serum for endogenous fluorochemicals, including a focus on PFOA and PFOS, using solid phase extraction and liquid chromatography/tandem mass spectrometry, while noting that data for PFBA was excluded due to instability issues.
|
2004 |
AR226-3576
|
YjZzOz8bJO6dv4M2w1OEpkBJO |
19 |
|
This analytical report from 3M Environmental Laboratory details the quantitative screening of thirty-six commercial lots of human serum for endogenous fluorochemicals, including PFOA and PFOS, using solid phase extraction and liquid chromatography/tandem mass spectrometry, although data for PFBA was excluded due to instability issues.
|
2004 |
AR226-3578
|
dYR6oKNJkE9rdd1MVKnyegV80 |
19 |
|
This analytical report from 3M Environmental Laboratory details the screening of thirty-six lots of commercially available human serum for sixteen endogenous fluorochemicals, including the exclusion of heptafluorobutyric acid (PFBA) due to instability, with plans for a separate study to analyze PFBA using a new method.
|
2004 |
AR226-3580
|
0JJ8JGGq3aQ6YqE2V39k2Nrvd |
19 |
|
Empty document.
|
2003 |
AR226-3632
|
52eqQQ7D7210edvBbKxmbm90 |
1 |
|
3M Company submitted studies to the EPA on May 23, 2003, regarding exploratory 28-day oral toxicity studies of various perfluorinated compounds, indicating that the data may warrant Section 8(e) submission due to potential implications for previously reported information.
|
2003 |
AR226-3656
|
jN4VomGXNQkG75ajj5VMDQrp |
3 |